Please login to the form below

Not currently logged in

Phase 1/2a results for J&J’s COVID-19 vaccine show early promise

Vaccine produced neutralising antibodies in 98% of participants

Results from a phase 1/2a study of Johnson & Johnson’s (J&J) potential COVID-19 vaccine candidate have come back positive, as the company’s launches a large-scale phase 3 trial across three continents.

According to interim results published on the pre-print server medRxiv on Friday, a single dose of J&J’s JNJ-78436735/Ad26.COV2.S vaccine produced a strong immune response against the novel coronavirus, SARS-CoV-2, which causes COVID-19.

The pre-print results have not been certified by peer review, but given the speed at which drugmakers like J&J are developing their COVID-19 vaccines, there is less time to follow traditional protocol with regards to publishing trial data.

Researchers from J&J’s pharmaceutical division Janssen said, from data available at the interim analysis, 98% of participants had neutralising antibodies 29 days after vaccination. The levels of neutralising antibodies in the vaccine treatment group were in the same range as people who have recovered from COVID-19 infections.

In addition, 99% of participants had developed detectable antibodies, while the candidate also elicited strong antibody responses, strong T-cell responses and a Th1 response. The Th1 response is believed to protect against the risk of vaccine-associated enhanced respiratory disease.

High levels of neutralising antibodies are an important indicator of efficacy in early clinical trials, as they defend cells from pathogens, including SARS-CoV-2.

Although the results are promising and have led to a 60,000-participant phase 3 trial, only a small number of immune response results for people over the age of 65 were available at the time of the interim analysis.

In addition, J&J reported that similar immunogenicity was observed across both dose levels, although it added that it has selected the lower dose for further clinical evaluation.

The 1,000-person phase 1/2a trial was supported by the US government’s Biomedical Advanced Research and Development Authority (BARDA), which has collectively committed $1bn to the vaccine project.

In July, J&J’s shot induced a robust immune response in early animal studies, demonstrated by high levels of neutralising antibodies. None of the six animals that received a single immunisation with J&J’s vaccine showed any detectable virus in their lower respiratory tract after exposure to SARS-CoV-2, and only one showed very low levels of the virus in a nasal swab at two time points.

Article by
Lucy Parsons

28th September 2020

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company Events and Exhibition Stands is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

1000 Voices Survey
The patient voice is key to creating meaningful changes in healthcare; to drive patients to be more actively involved in their care, which leads to better outcomes. So, we went...
COVID-19 vaccine
How will COVID-19 affect uptake of vaccinations against other diseases?
Will COVID-19 help or hinder the quest to increase uptake of other vaccinations?...
How community outreach can help improve diversity in clinical research
To execute a considered community engagement strategy, an involved and collaborative process is needed....